Data / Drug companies / Roerig
Roerig: 27 products in the FDA NDC directory, labeler code 0049
Roerig (labeler code 0049) lists 27 products in the FDA National Drug Code Directory, covering 8 finished drugs by generic name. By type: 25 prescription drugs, 2 drugs for further processing. Its main marketing category is new drug applications (NDA). The newest product started marketing on February 20, 2024.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0049
- Products in commercial distribution
- 27
- Packages
- 28
- Finished drugs by generic name
- 8
- Prescription products
- 25
- Over the counter products
- 0
- Flagged as original packager
- 20 of 20 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 7
- Earliest marketing start
- November 22, 1991
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 20 | 74.1% |
| Generic drugs (ANDA) | 5 | 18.5% |
| Export only | 2 | 7.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 25 | 92.6% |
| Drugs for further processing | 2 | 7.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Penicillin g potassium | 5 | 8 |
| Voriconazole | 5 | 34 |
| Ziprasidone | 4 | 7 |
| Anidulafungin | 3 | 1 |
| Ampicillin sodium and sulbactam sodium | 3 | 7 |
| Doxazosin | 3 | 28 |
| Glipizide | 1 | 39 |
| Fluconazole | 1 | 48 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 6 | 22.2% |
| Powder, for solution | 5 | 18.5% |
| Capsule | 4 | 14.8% |
| Injection, powder, for solution | 3 | 11.1% |
| Tablet | 3 | 11.1% |
| Tablet, extended release | 3 | 11.1% |
| Powder, for suspension | 2 | 7.4% |
| Tablet, film coated | 1 | 3.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Penicillin-class Antibacterial | 8 |
| Azole Antifungal | 6 |
| Atypical Antipsychotic | 4 |
| Echinocandin Antifungal | 3 |
| beta Lactamase Inhibitor | 3 |
| alpha-Adrenergic Blocker | 3 |
| Sulfonylurea | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Eraxis | 0049-2242 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | February 20, 2024 |
| Geodon | 0049-0354 | Capsule | New drug applications (NDA) | July 14, 2023 |
| Cardura | 0049-2716 | Tablet | New drug applications (NDA) | February 15, 2023 |
| Geodon | 0049-0358 | Capsule | New drug applications (NDA) | November 8, 2021 |
| Geodon | 0049-0356 | Capsule | New drug applications (NDA) | November 8, 2021 |
| Geodon | 0049-0352 | Capsule | New drug applications (NDA) | November 8, 2021 |
| Cardura | 0049-2614 | Tablet | New drug applications (NDA) | October 19, 2021 |
| Cardura | 0049-2512 | Tablet | New drug applications (NDA) | October 19, 2021 |
| Glipizide | 0049-1582 | Tablet, extended release | Export only | May 9, 2013 |
| Glipizide | 0049-1581 | Tablet, extended release | Export only | May 9, 2013 |
| Glucotrol XL | 0049-0174 | Tablet, extended release | New drug applications (NDA) | May 9, 2013 |
| Vfend | 0049-4190 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | October 24, 2012 |
| Pfizerpen | 0049-0530 | Powder, for solution | Generic drugs (ANDA) | June 1, 2010 |
| Pfizerpen | 0049-0520 | Powder, for solution | Generic drugs (ANDA) | June 1, 2010 |
| Pfizerpen | 0049-0520 | Powder, for solution | Generic drugs (ANDA) | June 1, 2010 |
| Pfizerpen | 0049-0430 | Powder, for solution | Generic drugs (ANDA) | June 1, 2010 |
| Pfizerpen | 0049-0420 | Powder, for solution | Generic drugs (ANDA) | June 1, 2010 |
| Eraxis | 0049-0116 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | February 17, 2006 |
| Eraxis | 0049-0114 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | February 17, 2006 |
| Vfend | 0049-3190 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | March 28, 2003 |
| Vfend | 0049-3180 | Tablet, film coated | New drug applications (NDA) | March 28, 2003 |
| Vfend | 0049-3160 | Powder, for suspension | New drug applications (NDA) | March 28, 2003 |
| Vfend | 0049-3190 | Injection, powder, lyophilized, for solution | New drug applications (NDA) | May 24, 2002 |
| Diflucan | 0049-3450 | Powder, for suspension | New drug applications (NDA) | December 23, 1993 |
| Unasyn | 0049-0024 | Injection, powder, for solution | New drug applications (NDA) | November 22, 1991 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.